These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 368881)

  • 21. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolytic agents: a perspective.
    Genton E; Pechet L
    Ann Intern Med; 1968 Sep; 69(3):625-8. PubMed ID: 5673180
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of epsilon-aminocaproyl-S-benzyl-L-cysteine on the activity of plasminogen activators.
    Bruzgo I; Midura-Nowaczek K; Kaczyńska J; Krajewska D
    Acta Pol Pharm; 2009; 66(1):37-40. PubMed ID: 19226966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ; Gresalfi N; Daly D; Oberhardt B; Tate DA
    J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparative ex vivo study of plasminogen activators and proteases for fibrinolytic activity and side effects in rabbits.
    Janik BA; Papaioannou SE
    Thromb Haemost; 1977 Feb; 37(1):154-61. PubMed ID: 576512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
    Spiecker M; Heinke B; Meyer J; Darius H
    Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombolytic agents: efficacy in relation to evolution time and dose].
    García Frade LJ; Torrado MC; Loren M; Navarro JL
    Rev Clin Esp; 1989 Feb; 184(2):75-9. PubMed ID: 2502822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Registry of prospective clinical trials second report.
    Verstraete M
    Thromb Haemost; 1976 Aug; 36(1):239-50. PubMed ID: 1036815
    [No Abstract]   [Full Text] [Related]  

  • 30. Mode of action and pharmacology of saruplase.
    Vermeer F
    Int J Clin Pract Suppl; 1998 Nov; 99():6-8. PubMed ID: 10344034
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular mechanisms of thrombolytic therapy.
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 3():3-15. PubMed ID: 2945766
    [No Abstract]   [Full Text] [Related]  

  • 32. [Acyl enzymes and pro-urokinase: promising new thrombolytic agents].
    Samama M; Horellou MH; Nguyen G; Conard J
    Haemostasis; 1986; 16 Suppl 4():35-9. PubMed ID: 3095199
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction].
    Bassand JP; Cassagnes J; Machecourt J; Anguenot T; Lusson JR; Borel E; Schiele F; Wolf JF; Vachet D
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():31-6. PubMed ID: 2108644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of thrombolysis: implications for therapy.
    Collen D; Lijnen HR
    Biochem Pharmacol; 1990 Jul; 40(2):177-86. PubMed ID: 2115776
    [No Abstract]   [Full Text] [Related]  

  • 36. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tissue plasminogen activator].
    Matsuo O
    Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
    [No Abstract]   [Full Text] [Related]  

  • 40. Methods for studying fibrinolytic pathway components in human plasma.
    Wohl RC; Sinio L; Robbins KC
    Thromb Res; 1982 Sep; 27(5):523-35. PubMed ID: 6217585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.